Liver Ablative Radiotherapy utilizing Kilovoltage intrafraction monitoring (KIM)

Stereotactic Ablative Body Radiotherapy (SABR) is an established treatment for both primary and secondary liver malignancies and is a highly effective treatment, but precise dose delivery is challenging due to organ motion. Currently, there is a lack of widely available options for performing real-time tumour localisation to assist with accurate delivery of liver SABR. This study will provide an assessment of the impact of Kilovoltage Intrafraction Monitoring (KIM) as a potential solution for real-time image guidance in liver SABR. It is hoped that this information will improve cancer targeting accuracy and lead to better patient outcomes in the future.

Primary Sponsor

University of Sydney (USYD)

Collaborating Groups

Trans Tasman Radiation Oncology Group (TROG)

Accrual Target

46

Final Accrual

46

Closing Date of Accrual

11 December 2023

Trial Chairperson

Dr Yoo Young (Dominique) Lee, Princess Alexandra Hospital, QLD

Dr Tim Wang, Crown Princess Mary Cancer Centre, Westmead, NSW

Trial Contact

LARK@trog.com.au

Clinical Trial Registration

Related Post

ESTRO26 presentation
20 May, 2026

TROG trials in the spotlight at ESTRO26 international conference

LATEST NEWS: 20 MAY A number of TROG trials

18 May, 2026

FASTRACK II trial finds emerging radiotherapy technique effectively controls kidney cancer

LATEST NEWS: 18 MAY 2026 A new non-invasive form